BioClarus Insights

Cologuard: test sensitivity is the start of a screening pathway

Original research published

Conceptual colon anatomy beside an unbranded specimen kit and diagnostic laboratory. Not a product photograph or diagnostic image.

A test result is one part of a screening pathway. Clarus Review uses the original 2014 Cologuard study and regulatory record to connect diagnostic performance with false-positive follow-up, referral capacity and completed care. The historical sensitivity and specificity findings belong to their stated study populations and denominators; they are not a comparison of every current test version.

The article emphasizes that a positive screening result requires its appropriate diagnostic follow-up. A returned kit, a valid result and a completed care pathway are therefore different milestones. The pivotal study does not establish routine-care completion rates, current coverage terms or a universal economic value.

An implementation plan should track ordered kits, usable samples, communicated results, completed follow-up and the interval between those steps. Outreach, repeat samples, laboratory work and follow-up capacity also affect the business case. The leadership implication is to connect technical performance to an actionable service before treating a diagnostic milestone as demonstrated adoption or health-economic success. This is a historical case summary, not current screening advice.

Read the full Clarus Biotech Review article

Sources

  1. pubmed.ncbi.nlm.nih.gov/24645800/
  2. www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm

Deep Domain Expertise Across Therapeutic Areas